Clinical Trial Update: Effects Of GW679769 On Sleep Onset And Maintenance And Next Day Functioning In Subjects With Primary Insomnia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated GW679769 for sleep onset, sleep maintenance, and next-day functioning in adults with primary insomnia. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia

Drugs mentioned

• GW679769

Snippet

Sponsor: GlaxoSmithKline | Conditions: Sleep Initiation and Maintenance Disorders, Insomnia | Phase 2 | Status: COMPLETED